Natera nabs ADLT status

By staff writers

June 21, 2021 -- The U.S. Centers for Medicare and Medicaid Services (CMS) awarded cell-free DNA testing company Natera advanced diagnostic laboratory test (ADLT) status for its Signatera molecular residual disease (MRD) test.

The test can monitor treatment and is able to detect cancer recurrence up to two years before conventional imaging, according to the firm.

Achieving ADLT status confirms Signatera meets the highly selective criteria established under the Protecting Access to Medicare Act of 2014 (PAMA), according to Natera. The initial ADLT rate is $3,500 for each Signatera assay used in the recurrence monitoring setting.

In late 2020, Signatera was covered under Medicare for use in stage II-III colorectal cancer. Finalization of a draft local coverage determination for use in immunotherapy response monitoring is anticipated for release later this year, the firm said.

Natera and Guardant Health embroiled in legal battle
Cell-free DNA testing company Natera and oncology firm Guardant Health have filed dueling false-advertising legal claims over oncology diagnostic tests.
Natera, Personalis team up on personalized oncology
Cell-free DNA testing company Natera and advanced genomics firm Personalis have partnered on a personalized oncology project targeted at the assessment...
Natera prenatal test gets extended insurance coverage
Healthcare insurer Centene has extended coverage of Natera's Panorama noninvasive prenatal test to all pregnant women. Panorama identifies a fetus's risk...
Natera wins Medicare coverage for colorectal cancer test
Natera has received local coverage determination from the U.S. Centers for Medicare and Medicaid Services for serial use of the Signatera molecular residual...
Natera to collaborate with MGH on breast cancer trial
Natera plans to collaborate with Massachusetts General Hospital (MGH) on a clinical trial that will test the effectiveness of ribociclib (Kisqali) in...

Copyright © 2021

Last Updated np 9/1/2021 12:27:37 PM